The Chair of the FTC Lina Kahn said she aims to challenge more corporate mergers and monopolistic practices, as well as adopt regulations to head off what she sees as unfair business tactics, reported The Wall Street Journal.
According to the WSJ those plans have sparked policy disagreements with Republican commissioners and produced discontent among career officials who have felt like an afterthought in her agenda. They say staffers, including some at senior levels of the agency, have felt excluded from deliberations and believe their views aren’t valued.
Last week this discontentment was made public when one of the FTC’s two Republican commissioners, Christine Wilson, gave a speech at an American Bar Association conference in which she said the commission’s current leadership “has sidelined and disdained our staff.”
“Leadership routinely fails to solicit the advice of our experienced staff,” Ms. Wilson said, adding that the current environment had prompted some staffers to leave, reported the WSJ.
Following Ms. Wilson’s speech, Ms. Khan sent out a commission-wide internal memo to address “commentary about the environment at the agency,” saying she cared deeply about the FTC’s mission and the staff.
“I know that there are still many relationships and bridges to build, and I am eager to do so as we chart this path forward together,” she wrote.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan